The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new
angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary …

Objective: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …

Objective: To compare the efficacy, safety and tolerability of valsartan to an angiotensin-
converting enzyme (ACE) inhibitor, lisinopril, and placebo in patients with mild-to-moderate …

A multicenter, randomized, placebo-controlled, double-masked, parallel-group study was
performed to compare the efficacy and safety of valsartan 20, 80, 160, and 320 mg with …

This patient data meta‐analysis included 9 randomized, double‐blind, placebo‐controlled
trials (N= 4278) of once‐daily valsartan 80, 160, or 320 mg or valsartan/hydrochlorothiazide …

Background: Losartan, the first of the angiotensin II receptor blockers (ARBs) to be
introduced, has been studied extensively in comparison with other classes of …

Objective: To compare the antihypertensive efficacy of a new angiotensin II antagonist,
valsartan, with a reference therapy, hydrochlorothiazide (HCTZ). Methods: In this double …

Objective: To study the efficacy and tolerability of a range of valsartan doses in patients with
mild-to-moderate hypertension. Design: 122 adult out-patients were randomised in equal …

Objective: This study compared the efficacy and tolerability of two combination regimens of
valsartan and hydrochlorothiazide (HCTZ) with valsartan monotherapy in patients with …

The long-term safety data on angiotensin II receptor blockers in combination with thiazide
diuretics are limited. The present study reports on the long-term efficacy, safety, and …